|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/22 Nukkleus Inc. S-4 114:26M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: S-4 Registration Statement - Securities for a Merger HTML 11.30M
2: EX-3.1 Certificate of Incorporation of Nukkleus HTML 37K
3: EX-23.1 Consent of Rotenberg Meril Solomon Bertiger & HTML 30K
Guttilla, P.C., Independent Registered Public
Accounting Firm of Nukkleus.
4: EX-23.2 Consent of Marcum Bernstein & Pinchuk LLP, HTML 32K
Independent Registered Public Accounting Firm of
Brilliant.
11: EX-FILING FEES Filing Fee Table HTML 40K
5: EX-99.1 Consent of Jamal Khurshid to Be Named as A HTML 31K
Director
6: EX-99.2 Consent of Nicholas Gregory to Be Named as A HTML 31K
Director
7: EX-99.3 Consent of Brian Schwieger to Be Named as A HTML 31K
Director
8: EX-99.4 Consent of Daniel Marcus to Be Named as A Director HTML 31K
9: EX-99.5 Consent of Brian Ferrier to Be Named as A Director HTML 31K
10: EX-99.9 Consent of the Benchmark Company, LLC HTML 32K
17: R1 Document And Entity Information HTML 46K
18: R2 Condensed Consolidated Balance Sheets HTML 152K
19: R3 Condensed Consolidated Balance Sheets HTML 80K
(Parentheticals)
20: R4 Unaudited Condensed Consolidated Statements of HTML 164K
Operations and Comprehensive Loss
21: R5 Unaudited Condensed Consolidated Statements of HTML 115K
Changes in Stockholders? Equity
22: R6 Unaudited Condensed Consolidated Statements of HTML 34K
Changes in Stockholders? Equity (Parentheticals)
23: R7 Unaudited Condensed Consolidated Statements of HTML 158K
Cash Flows
24: R8 The Company History and Nature of The Business HTML 90K
25: R9 Basis of Presentation HTML 40K
26: R10 Summary of Significant Accounting Policies HTML 337K
27: R11 Acquisition HTML 65K
28: R12 Intangible assets HTML 132K
29: R13 Accounts Payable and Accrued Liabilities HTML 88K
30: R14 Share Capital HTML 171K
31: R15 Income Taxes HTML 224K
32: R16 Related Party Transactions HTML 216K
33: R17 Concentrations HTML 80K
34: R18 Segment Information HTML 460K
35: R19 Contingency HTML 49K
36: R20 Subsequent Events HTML 45K
37: R21 Investment, at Cost HTML 36K
38: R22 Initial Public Offering HTML 35K
39: R23 Private Placement HTML 36K
40: R24 Shareholders' Equity HTML 55K
41: R25 Derivative Warrant Liabilities HTML 37K
42: R26 Fair Value Measurements HTML 126K
43: R27 Accounting Policies, by Policy (Policies) HTML 375K
44: R28 Summary of Significant Accounting Policies HTML 228K
(Tables)
45: R29 Acquisition (Tables) HTML 60K
46: R30 Intangible assets (Tables) HTML 129K
47: R31 Accounts Payable and Accrued Liabilities (Tables) HTML 86K
48: R32 Share Capital (Tables) HTML 157K
49: R33 Income Taxes (Tables) HTML 221K
50: R34 Related Party Transactions (Tables) HTML 187K
51: R35 Concentrations (Tables) HTML 70K
52: R36 Segment Information (Tables) HTML 453K
53: R37 Fair Value Measurements (Tables) HTML 120K
54: R38 The Company History and Nature of The Business HTML 188K
(Details)
55: R39 Summary of Significant Accounting Policies HTML 102K
(Details)
56: R40 Summary of Significant Accounting Policies HTML 45K
(Details) - Schedule of cash balances by
geographic area
57: R41 Summary of Significant Accounting Policies HTML 44K
(Details) - Schedule of revenues are disaggregated
by segment
58: R42 Summary of Significant Accounting Policies HTML 39K
(Details) - Schedule of diluted net income (loss)
per share
59: R43 Acquisition (Details) HTML 50K
60: R44 Acquisition (Details) - Schedule of summarizes HTML 51K
total consideration transferred
61: R45 Intangible assets (Details) HTML 37K
62: R46 Intangible assets (Details) - Schedule of HTML 41K
intangible assets
63: R47 Intangible assets (Details) - Schedule of HTML 45K
amortization of intangible assets attributable to
future periods
64: R48 Accounts Payable and Accrued Liabilities (Details) HTML 45K
- Schedule of accounts payable and accrued
liabilities
65: R49 Share Capital (Details) HTML 149K
66: R50 Share Capital (Details) - Schedule of common stock HTML 45K
issuable upon exercise of options outstanding
67: R51 Share Capital (Details) - Schedule of stock option HTML 56K
68: R52 Share Capital (Details) - Schedule of nonvested HTML 43K
stock options granted
69: R53 Income Taxes (Details) HTML 44K
70: R54 Income Taxes (Details) - Schedule of net income HTML 42K
(Loss)
71: R55 Income Taxes (Details) - Schedule of income taxes HTML 55K
expense (Benefit)
72: R56 Income Taxes (Details) - Schedule of effective HTML 46K
income tax rate reconciliation
73: R57 Income Taxes (Details) - Schedule of deferred tax HTML 41K
assets
74: R58 Related Party Transactions (Details) HTML 118K
75: R59 Related Party Transactions (Details) - Schedule of HTML 44K
related party transaction
76: R60 Related Party Transactions (Details) - Schedule of HTML 39K
due from affiliates
77: R61 Related Party Transactions (Details) - Schedule of HTML 46K
due to affiliates
78: R62 Concentrations (Details) HTML 55K
79: R63 Concentrations (Details) - Schedule of customer HTML 37K
and supplier revenues
80: R64 Segment Information (Details) - Schedule of HTML 88K
reportable business segments
81: R65 Segment Information (Details) - Schedule of total HTML 39K
assets
82: R66 Contingency (Details) HTML 58K
83: R67 Subsequent Events (Details) HTML 59K
84: R68 Summary of Significant Accounting Policies HTML 45K
(Details) - Schedule of cash balances by
geographic area
85: R69 Summary of Significant Accounting Policies HTML 44K
(Details) - Schedule of revenues are disaggregated
by segment
86: R70 Summary of Significant Accounting Policies HTML 39K
(Details) - Schedule of diluted net income (loss)
per share
87: R71 Investment, at Cost (Details) HTML 39K
88: R72 Intangible Assets (Details) - Schedule of HTML 60K
intangible assets
89: R73 Intangible Assets (Details) - Schedule of HTML 45K
amortization of intangible assets attributable to
future periods
90: R74 Accounts Payable and Accrued Liabilities (Details) HTML 43K
- Schedule of accounts payable and accrued
liabilities
91: R75 Share Capital (Details) - Schedule of common stock HTML 47K
issuable upon exercise of options outstanding
92: R76 Share Capital (Details) - Schedule of stock option HTML 52K
activities
93: R77 Share Capital (Details) - Schedule of nonvested HTML 45K
stock options granted
94: R78 Related Party Transactions (Details) - Schedule of HTML 44K
related party transaction
95: R79 Related Party Transactions (Details) - Schedule of HTML 39K
due from affiliates
96: R80 Related Party Transactions (Details) - Schedule of HTML 46K
due to affiliates
97: R81 Concentrations (Details) - Schedule of customer HTML 37K
and supplier revenues
98: R82 Segment Information (Details) - Schedule of HTML 87K
reportable business segments
99: R83 Segment Information (Details) - Schedule of total HTML 39K
assets
100: R84 Summary of Significant Accounting Policies HTML 42K
(Details) - Schedule of ordinary shares reflected
in the balance sheets
101: R85 Summary of Significant Accounting Policies HTML 39K
(Details) - Schedule of loss per ordinary share
102: R86 Initial Public Offering (Details) HTML 45K
103: R87 Private Placement (Details) HTML 44K
104: R88 Shareholders' Equity (Details) HTML 64K
105: R89 Derivative Warrant Liabilities (Details) HTML 35K
106: R90 Fair Value Measurements (Details) HTML 36K
107: R91 Fair Value Measurements (Details) - Schedule of HTML 41K
company?s assets and liabilities that are measured
at fair value on a recurring basis
108: R92 Fair Value Measurements (Details) - Schedule of HTML 42K
Level 3 fair value measurements inputs of
company?s warrants at their measurement dates
109: R93 Fair Value Measurements (Details) - Schedule of HTML 38K
fair value of the derivative warrant liabilities
112: XML IDEA XML File -- Filing Summary XML 214K
110: XML XBRL Instance -- fs42022_nukkleusinc_htm XML 4.47M
111: EXCEL IDEA Workbook of Financial Reports XLSX 143K
13: EX-101.CAL XBRL Calculations -- nukk-20211231_cal XML 116K
14: EX-101.DEF XBRL Definitions -- nukk-20211231_def XML 1.31M
15: EX-101.LAB XBRL Labels -- nukk-20211231_lab XML 2.01M
16: EX-101.PRE XBRL Presentations -- nukk-20211231_pre XML 1.25M
12: EX-101.SCH XBRL Schema -- nukk-20211231 XSD 351K
113: JSON XBRL Instance as JSON Data -- MetaLinks 490± 674K
114: ZIP XBRL Zipped Folder -- 0001213900-22-020178-xbrl Zip 1.18M
Exhibit 99.9
CONSENT OF THE BENCHMARK COMPANY, LLC
Brilliant Acquisition Corporation
99 Dan Ba Road, C-9, Putuo District,
Shanghai, Peoples Republic of China
The Board of Directors:
We hereby consent to the inclusion of our opinion letter, dated April 6, 2022, to the Board of Directors of Brilliant Acquisition Corporation (“Brilliant”) as Annex B to, and reference thereto under the headings, “Questions and Answers about the Proposals,” “Summary of the Proxy Statement—Opinion of The Benchmark Company, LLC,” “Brilliant Proposal 1 – The Brilliant Business Combination Proposal—Background of the Business Combination” and “—Opinion of Brilliant’s Financial Advisor” in, the joint proxy statement/prospectus relating to the proposed business combination involving Brilliant and Nukkleus Inc. (“Nukkleus”), which joint proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of Nukkleus (the “Registration Statement”). By giving such consent, we do not thereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term “expert” as used in, or that we come within the category of persons whose consent is required under, the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
| Very truly yours, | |
| /s/ The Benchmark Company, LLC | |
| The Benchmark Company, LLC | |
| April 12, 2022 |
| This ‘S-4’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/15/22 | None on these Dates | ||
| 4/12/22 | ||||
| 4/6/22 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/02/22 Nukkleus Inc. S-4/A 127:39M EdgarAgents LLC/FA 10/03/22 Nukkleus Inc. S-4/A 9/30/22 127:38M EdgarAgents LLC/FA 8/09/22 Nukkleus Inc. S-4/A 131:37M EdgarAgents LLC/FA 6/13/22 Nukkleus Inc. S-4/A 120:33M EdgarAgents LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/22 Nukkleus Inc. 8-K:1,7,9 2/22/22 15:1M EdgarAgents LLC/FA 8/09/16 Nukkleus Inc. 8-K:1,5,9 8/01/16 7:308K S2 Filings LLC/FA 6/03/16 Nukkleus Inc. 8-K:1,3,9 5/27/16 9:625K Blueprint/FA |